Global Drug Delivery Across Blood Brain Barrier Market by Drug Delivery Technology (Trojan Approach, Increasing Permeability) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

In 2018, the global market for drug delivery across blood-brain barrier was valued at USD 582.0 millions. The market is expected to grow due to increasing incidences of neurological disorders such as Alzheimer's, Parkinson's, Hunter's syndrome and brain tumors over the forecast period.

Another driver is the increasing prevalence of dementia in the elderly population. Globally, 50 million people have been diagnosed with dementia. 60-70% of Alzheimer's patients are affected by this condition. The condition is also known as vascular dementia. There are other disorders such as frontotemporal dementia and dementia with Lewy body. This market will be driven by the rising incidence of dementia.

The healthcare industry is seeing a rise in use of nanotechnology to treat various medical conditions. The treatment of many chronic diseases can be made easier by nanotechnology. This is possible through the targeted and precise delivery of medicines to specific sites. Nanobiotechnology is also useful in the facilitation and delivery of drugs across the blood-brain barrier. Hence, the growing use of nanobiotechnology-based drug delivery for brain tumors is also driving the market.

There are few problems with nanoparticle-based drug delivery. However, there is still much to be done. One of the key advantages of NP-based drug-delivery technology is its ability to overcome the blood-brain barrier, which limits the property of the therapeutic drugs module. Nanoparticles also reduce drug release speed in the brain, which lowers peripheral toxicities.

There is a growing demand for drug delivery technology to treat neurological disorders such as brain cancer, brain tumors, multiple sclerosis, chronic cerebral ischemia, multiple and acute brain tumors, and multiple sclerosis. According to The Lancet Neurology neurological disorders are the second most common cause of death worldwide. The growth in research and applications in this area is expected to drive the use of nanoparticles for drug delivery across the blood brain barrier market.

Drug Delivery Technology Insights

Technology-wise, the market can be divided into the Trojan horse, bispecific anti RMT approach and increasing the permeability BBB. Passive diffusion and other non-invasive BBB technology are also available. Due to the increasing number of research activities in treating neurological and CNS (Central Nervous System), disorders, the market for drug delivery across blood-brain barriers has seen a significant increase in BBB permeability.

For the treatment of brain tumors, novel drug delivery technologies are being investigated. They can be used to overcome the side effects and drawbacks of traditional methods. The segment is expected to grow with increasing innovation and research in drug delivery technologies in various nanoparticle and physical systems.

The Trojan horse approach segment will also grow significantly over the forecast period, due to increasing use of biologics to treat CNS disorders and the high permeability for blood-brain barrier. The new treatment for most CNS disorders is biologics. Biologics are preferred because they deliver specific materials to brains by fighting with proteins that cross the barrier.

Application Insights

The market can be divided by application into Alzheimer's disease, Epilepsy and Parkinson's disease, multiple sclerosis, Parkinson's, Multiple Sclerosis, Hunter's Syndrome, brain cancer, and other conditions. Due to its high prevalence, Parkinson's disease accounted for the highest drug delivery in the blood-brain market.

Segment growth is expected to be driven by the growing incidence of epilepsy. The World Health Organization (WHO) estimates that epilepsy affects approximately 50 million people. Epilepsy is also a more common neurological disorder than others. This is why EU safety standards require that epileptic incidence trigger devices/electronics are mentioned. Epilepsy sufferers are at risk of dying before their third birthday due to the overwhelming nature of seizures that can be induced by an attack.

The Hunter's syndrome segment will also grow rapidly. Introduction of therapies, such as enzyme replacement therapy incorporated with recombinant iduronate-2-sulphatase (idursulfase) in the drug delivery for improving the symptoms of the targeted disorder is expected to boost the segment growth.

Regional Insights

The market can be divided into North America, Europe and Asia Pacific as well as Middle East & Africa. North America accounted for a large share of the market due to its high prevalence of Hunter's & Alzheimer’s syndrome and innovative treatments for severe life-threatening conditions.

Asia Pacific will also see the fastest growth of this market during the forecast period due to an increase in neurological disorders and a growing number of geriatrics who are susceptible to brain and CNS disorders. The market will also be driven by the growth of the medical tourism industry as well as long-term care facilities.

The future growth of the regional market is expected to be driven by rising healthcare spending for long-term care patients, increased investment in pharmaceutical research and development, increasing awareness for chronic neurological conditions, and growing awareness campaigns about neurological disorders.

Market Share Insights: Drug Delivery across the Blood-Brain Barrier

Ossianix, Inc., Insightec, Angiochem Inc., Armagen Technologies, Inc., BrainsGate, BiOasis Technologies, Inc., BrainsGate, BrainsGate, BiOasis Technologies, Inc., CarThera, F. Hoffman La-Roche, Iproteos S.L. are just a few of the players in this market. These players focus on growth strategies such as innovation in therapeutic techniques, R&D to introduce modern techniques for curing neurologic disorders, awareness campaigns in untapped areas of developing economies, mergers and acquisitions with innovative companies, and many more.

Ossianix, Inc., a pioneer in the BBB market, recently announced a research agreement and agreement with Novo Nordisk, an international pharmaceutical company. This collaboration will provide therapeutic molecules for severe disorders that cross the blood-brain barrier and to the brain. The agreement states that Ossianix Company will use the copyright single domain VNAR antibody antibodies to deliver a determined number of therapeutic agents from Novo Nordisk. Novo Nordisk will remain responsible for the commercialization and launch of these healing products.

Market Report Scope Drug Delivery Across Blood Brain Barriers

The report covers segments

This report predicts revenue growth at the global, regional and country levels. It also analyzes the industry trends for each sub-segment from 2015 to 2026. Grand View Research has divided the global blood-brain barrier drug delivery market by drug delivery technology, region, and application.

• The Drug Delivery Technology Outlook (Revenue USD Millions, 2016-2026)

  • Trojan Horse Approach

  • Bispecific Antibody RMT Approach

  • BBB Permeability - Increasing

  • Passive Diffusion

  • Other non-invasive BBB Technologies

• App Outlook (Revenue USD Million, 2016-2026)

  • Alzheimer's Disease

  • Epilepsy

  • Parkinson's Disease

  • Multiple Sclerosis

  • Hunter's Syndrome

  • Brain Cancer

  • Other

• Regional Outlook (Revenue USD Million, 2016-2026)

  • North America

    • The U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

  • Asia Pacific

    • Japan

    • China

    • India

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

These are the most frequently asked questions about this report

b. Global drug delivery across blood brain barriers market size was USD 731.5 Million in 2019, and is forecast to rise to USD 881 Million in 2020.

b. Global drug delivery across blood brain barriers market is expected grow at a compound annual rate of 30.2% between 2019 and 2026, to reach USD 4,627.3 Million by 2026

b. With a 49.21% share in 2019, North America was the dominant market for drug delivery across blood brain barriers. This can be attributed to Hunter's and Alzheimer's disease rising in prevalence, as well as the development of new techniques to treat severe life-threatening conditions.

b. Ossianix, Inc., Insightec, Angiochem Inc., Armagen Technologies, Inc., BrainsGate, BiOasis Technologies, Inc., CarThera, F. Hoffman La-Roche, Iproteos S.L. are some of the key players in the blood brain barrier drug delivery market.

b. The market's growth is being driven by the increasing incidence of neurological disorders such as Alzheimer's, Parkinson's, Hunter's syndrome and brain tumor.

Up Market Research published a new report titled “Drug Delivery Across Blood Brain Barrier Market research report which is segmented by Drug Delivery Technology (Trojan Approach, Increasing Permeability), By Players/Companies Armagen Technologies, Inc, Inc, Ossianix, BiOasis Technologies, BrainsGate, Iproteos SL, Inc, Angiochem Inc, CarThera, Insightec, F Hoffman La-Roche”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

Report Scope

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Drug Delivery Across Blood Brain Barrier Market Report Segments:

The market is segmented by Drug Delivery Technology (Trojan Approach, Increasing Permeability).

Drug Delivery Across Blood Brain Barrier Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Drug Delivery Across Blood Brain Barrier Market

Overview of the regional outlook of the Drug Delivery Across Blood Brain Barrier Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Drug Delivery Across Blood Brain Barrier Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Drug Delivery Across Blood Brain Barrier Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Trojan Approach

                2. Increasing Permeability

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Drug Delivery Across Blood Brain Barrier Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Drug Delivery Across Blood Brain Barrier Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.